08:07 AM EDT, 10/13/2025 (MT Newswires) -- Precigen ( PGEN ) said Monday that follow-up data from a clinical study showed durable outcomes in 83% of adult recurrent respiratory papillomatosis patients treated with its drug Papzimeos.

The company said 15 out of the 18 complete responders in the study that supported the drug's US Food and Drug Administration approval showed continued response after one year.

Patients also showed an 86% reduction in the requirement for surgical intervention at year one compared to before the treatment, 91% in year two, and 95% in year three, the company said.

Recurrent respiratory papillomatosis is a rare, debilitating, and potentially life-threatening disease affecting the upper and lower respiratory tract.

Shares of the company were up over 4% in recent premarket activity.